<DOC>
	<DOC>NCT01643772</DOC>
	<brief_summary>A Single Dose PK Study of OxyNorm® immediate-release capsules 5, 10, and 20mg, and a multiple-dose PK Study of OxyNorm® immediate-release capsules 10mg in Chinese patients with pain.It will be a single center, open label, randomized, oral administration study.</brief_summary>
	<brief_title>OxyNorm® Capsules (Immediate-Release) Pharmacokinetic (PK) Study</brief_title>
	<detailed_description>Single dose: The subjects will be randomized to receive a single dose of OxyNorm® immediate-release capsules 5, 10, and 20mg. Multiple dose: The subjects will take 3 days OxyNorm® capsule 10mg, once every 6 hours, 10mg per dose. In the morning of the 4th day, the subjects will take single dose of OxyNorm® capsule 10mg. On the 5th day, all the subjects complete the study.</detailed_description>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Patients with pain, Multiple dose group should enroll the Patients with cancer pain; Patients aged &gt;≥30 to ≤ 60 years; Body weight ≥ 45kg, and BMI range ≥19, &lt;24; Karnofsky score ≥ 70; The results of liver function and kidney tests must meet the following criteria: ALT、AST is within the upper limit of normal value ranges by a factor 2, and TB、BUN、Cr is within the upper limit of normal value ranges by a factor 1.25; The electrocardiogram examination results are normal; Patients must have given a written informed consent prior to this trial, and have the capability to complete every required test. Have hypersensitivity history to any opioids; Have known hypersensitivity to any of compositions of the study drugs; Patients who are likely to have paralytic ileus or acute abdomen or to perform an operation on abdominal region； Patients with respiratory depression, cor pulmonale, or chronic bronchial asthma; Patients who are unable to stop taking monoamine oxidase inhibitor during this trial period or time lapses less than 2 weeks since drug withdrawal; Patients with hypercarbia; Patients with biliary tract diseases, pancreatitis, prostatic hypertrophy, or corticoadrenal insufficiency; Patients with alcoholism or drug abuse history; Positive antiHIV or syphilis antibody test result; Patients who are pregnant, or lactating; Urine screening before study is positive for opioids, barbiturates, amphetamines, cocaine metabolites, methadone, diazepam and cannabinoids; Donated 400 mL or more of blood or blood products within 3 months prior to the start of the study, or donated 200 mL or more of blood or blood products within one month prior to the start of the study; Subjects who participated in a clinical research study within one month of study entry; Patients who are currently taking opioids.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>